We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
-12.61%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$2.9B
AUM Growth
-$300M
Cap. Flow
+$226M
Cap. Flow %
7.79%
Top 10 Hldgs %
60.65%
Holding
101
New
14
Increased
15
Reduced
4
Closed
21

Top Buys

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$145M
2
ARVN icon
Arvinas
ARVN
+$81.3M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$58.7M
4
RVMD icon
Revolution Medicines
RVMD
+$58.5M
5
ALLO icon
Allogene Therapeutics
ALLO
+$39.8M

Top Sells

Rank Stock Value
1
RCUS icon
Arcus Biosciences
RCUS
+$103M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$41.2M
3
PCVX icon
Vaxcyte
PCVX
+$31.5M
4
BCYC
Bicycle Therapeutics
BCYC
+$24M
5
EXEL icon
Exelixis
EXEL
+$19.6M

Sector Composition

Rank Sector Weight
1 Healthcare 98.48%
2 Financials 0.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EVLO
76
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
$423K 0.01%
+10,021
New +$465K
CMAXW
77
DELISTED
CareMax, Inc. Warrant
CMAXW
$363K 0.01%
100,000
– –
TMPMW
78
DELISTED
Turmeric Acquisition Corp. Warrant
TMPMW
$331K 0.01%
33,333
– –
BOLT icon
79
Bolt Biotherapeutics
BOLT
$7.72M
$306K 0.01%
7,500
– –
SRZNW icon
80
Surrozen Inc Warrant
SRZNW
$41.9K
$200K 0.01%
66,665
– –
ACIU icon
81
AC Immune
ACIU
$231M
– –
-485,005
Closed -$1.94M
BCYC
82
Bicycle Therapeutics
BCYC
$275M
– –
-547,453
Closed -$24M
CCCC icon
83
C4 Therapeutics
CCCC
$389M
– –
-200,000
Closed -$4.85M
CRBU icon
84
Caribou Biosciences
CRBU
$161M
– –
-75,000
Closed -$689K
EXEL icon
85
Exelixis
EXEL
$14.1B
– –
-951,333
Closed -$19.6M
IGMS
86
DELISTED
IGM Biosciences
IGMS
– –
-298,597
Closed -$7.98M
MLTX icon
87
MoonLake Immunotherapeutics
MLTX
$1.65B
– –
-200,000
Closed -$2.22M
NRIX icon
88
Nurix Therapeutics
NRIX
$2.43B
– –
-254,473
Closed -$3.56M
PCVX icon
89
Vaxcyte
PCVX
$8.05B
– –
-1,304,741
Closed -$31.5M
PMVP icon
90
PMV Pharmaceuticals
PMVP
$63.5M
– –
-649,786
Closed -$13.5M
PTGX icon
91
Protagonist Therapeutics
PTGX
$8.86B
– –
-381,711
Closed -$9.04M
RCUS icon
92
Arcus Biosciences
RCUS
$3.6B
– –
-3,265,101
Closed -$103M
RPTX
93
DELISTED
Repare Therapeutics
RPTX
– –
-50,000
Closed -$712K
SLDB icon
94
Solid Biosciences
SLDB
$787M
– –
-171,007
Closed -$3.08M
SWTX
95
DELISTED
SpringWorks Therapeutics
SWTX
– –
-325,881
Closed -$18.4M
ZNTL icon
96
Zentalis Pharmaceuticals
ZNTL
$322M
– –
-115,236
Closed -$5.32M
BCEL
97
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
– –
-358,780
Closed -$1.14M
MRTX
98
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-500,622
Closed -$41.2M
AMTI
99
DELISTED
Applied Molecular Transport Inc. Common Stock
AMTI
– –
-131,693
Closed -$990K
EUCRW
100
CALL
DELISTED
Eucrates Biomedical Acquisition Corp. Warrant
EUCRW
– –
-66,666
Closed -$656K
1 2 3
4
5

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return
CIP
Cornerstone Investment Partners Atlanta, Georgia $2.38B AUM 32.49% 1-Year Est. Return

EcoR1 Capital's Q2 2022 Portfolio in Review

As of Q2 2022, EcoR1 Capital held 101 positions worth $2.9B, down 9.4% from $3.2B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

EcoR1 Capital deployed $226M of net new capital in Q2 2022, opening 14 new positions and adding to 15 existing holdings. Its largest new stake was Seagen Inc. Common Stock: 1,008,628 shares worth $178M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Alector, an estimated $16.8M trimmed.

  • EcoR1 Capital's largest Q2 2022 buy was Seagen Inc. Common Stock: 1,008,628 shares worth $178M.
  • EcoR1 Capital added most to Arvinas in Q2 2022, an estimated $81.3M increase.
  • EcoR1 Capital's biggest Q2 2022 reduction was Alector, cutting an estimated $16.8M.
  • EcoR1 Capital fully exited Arcus Biosciences in Q2 2022, selling an estimated $103M.
  • EcoR1 Capital's ten largest holdings make up 61% of its $2.9B portfolio in Q2 2022.
  • EcoR1 Capital opened 14 new positions and closed 21 in Q2 2022.
  • EcoR1 Capital's portfolio value fell 9.4% quarter-over-quarter to $2.9B.

Based on EcoR1 Capital's 13F filing for Q2 2022, filed 15 Aug 2022.